Healthcare

Neuren Pharmaceuticals Limited (ASX:NEU) advanced 6.819% to AUD 13.940 on 2 March 2026, adding AUD 0.889 during the session. Trading volume reached 397,825 shares, while the bid-offer range stood narrowly at AUD 13.930–13.940, suggesting firm positioning near closing levels.

The company, incorporated with ACN 619 459 335, operates from its headquarters at the Bio21 Institute in Parkville, Victoria. This prestigious location places RHY at the center of Australia's biomedical research hub, positioning the company alongside leading research institutions and complementary healthcare companies. The …

Uscom Limited (ASX:UCM) was, until late 2025, one of Australia's few publicly listed medical device companies with a genuinely global operational footprint. Founded and built around proprietary non-invasive cardiovascular monitoring technology — particularly its flagship USCOM device, which provides real-time haemodynamic monitoring without the …

Mesoblast Ltd (ASX:MSB) (Nasdaq:MESO) shares fell 7.02% to AUD 2.25 on 27 February 2026, following the release of its half-year financial results for the period ended 31 December 2025. The stock has declined 6.25% over the past five days and 8.54% over the past …

Biotron Ltd (ASX:BIT) shares declined 14.29% to AUD 0.0030 on 26 February 2026, extending the stock’s decline to approximately 70% over the past year. The latest price weakness followed the release of the company’s financial results for the half year ended 31 December 2025 …

Nanosonics Ltd (ASX:NAN) shares declined 3.85% to AUD 3.25 on 26 February 2026, extending the stock’s decline to approximately 30.85% over the past year. Today’s price movement coincided with the release of company’s latest update.

Cynata reported a net loss of $2.662 million for the half year ended 31 December 2025, representing a 27% improvement from the $3.650 million loss in the prior corresponding period.Revenueand other income totalled $1.772 million, down modestly from $1.970 million. While the narrowing loss …